IRCCS Humanitas Research Hospital
Dr Cappato is Principal Investigator for X-VERT (eXploring the efficacy and safety of oral rivaroxaban OD compared with that of dose-adjusted oral VKA for the prEvention of caRdiovascular events in patients with non-valvular aTrial fibrillation scheduled for cardioversion) and VENTURE-AF (randomized, open-label, actiVe-controlled multi-cENTer stUdy to evaluate the safety of Rivaroxaban and vitamin K antagonists in subjects undergoing cathEter ablation for Atrial Fibrillation) studies. Dr Cappato is also leading investigator of a patient-based worldwide atrial fibrillation ablation survey. He is the co-inventor of the sub-cutaneous implantable cardioverter defibrillator. He frequently serves as an invited speaker at major international meetings. He has published over 300 peer-reviewed journals and book chapters, and is on the editorial board of numerous Cardiology Journals.
Supraventricular and ventricular arrhythmias, Transcatheter radio-frequency